



Cite this: *RSC Adv.*, 2025, 15, 2329

Received 3rd December 2024

Accepted 12th January 2025

DOI: 10.1039/d4ra08525f

rsc.li/rsc-advances

Tetrazolium iridium complexes as potential antibacterial agents

Yifei Lu,^{†ab} Xiujuan Zhang,^{†a} Minmin Song,^a Hua Xie,^c Shuhua Chen,^d Yuyang Zhou,^{id}*^e Junli Jia^{*a} and Huamin Tang^{*af}

In this work, three iridium(III) tetrazolato complexes have been used in antibacterial, biofilm removal and for other bioactivities for the first time. Notably, these iridium(III) tetrazolato complexes with high antibacterial, especially, Ir-CF₃TAZ showed the best antimicrobial activity and the most effective hemolytic performance, which may pave the way to explore the value of the complexes for clinical applications in the future.

Introduction

Antimicrobial resistance has become one of the most significant challenges to global public health in the 21st century.¹ The World Health Organization (WHO) has identified that bacterial drug resistance can result in difficulties in treatment, prolonged duration of illness, increased mortality rates, and increased healthcare costs, which collectively impose a substantial economic burden on the global population.^{2,3} Therefore, the shortage of antibacterial drug stockpiles highlights the urgent need to search for new antibacterial drugs.

In recent years, there has been a notable increase in research activity surrounding metal coordination compounds, largely due to their distinctive antimicrobial mechanisms and the vast range of activities they exhibit. The distinctive characteristics of transition metals have prompted a growing interest in the design and synthesis of complexes for therapeutic applications.⁴ For example, cisplatin-based metal compounds have been widely employed in clinical tumour chemotherapy;⁵ lithium has been demonstrated to be efficacious in the treatment of acute mania and bipolar disorder;⁶ ruthenium complexes showed excellent antibacterial bioactive against *Staphylococcus aureus*;⁷ and a number of bismuth compounds have been shown to be effective in combination therapy for




Fig. 1 Structures of the complexes.

Helicobacter pylori infections.⁸ While metallic iridium(III) complexes have been identified as promising novel drug candidates. They have demonstrated antitumor and antiviral activities.^{9–11} Some of these complexes have been demonstrated to exhibit antibacterial capacity.^{12–14}

In our previous work, we synthesized tetrazolium iridium complexes (Fig. 1).¹⁵ This study systematically explored the antimicrobial properties of iridium(III) tetrazolato complexes for the first time. We hope that the findings presented in this paper will provide a theoretical foundation for the development of novel antibacterial agents and contribute to addressing the issue of bacterial drug resistance.

Results and discussions

Solid-phase antibacterial

Fig. 2 and Table 1 illustrate the performance and the sizes of the inhibition zones for the complexes at various concentrations. Compared to the positive control kanamycin, the antibacterial activity of Ir-CF₃TAZ was the most potent. In contrast, the antimicrobial effect of Ir-CH₃TAZ was minimal and showed no significant differences across different concentrations. Further results indicated that bacterial inhibition was dose-dependent.

Liquid-phase antibacterial

The inhibitory effects of the three complexes on bacterial growth diminished over the four-hour study period. Initially,

^aDepartment of Immunology, School of Basic Medical Sciences, Nanjing Medical University, Nanjing 211166, Jiangsu, P. R. China. E-mail: jljia2016@njmu.edu.cn; htang@njmu.edu.cn

^bFirst School of Clinical Medicine, Nanjing Medical University, Nanjing 211166, Jiangsu, P. R. China

^cJintan Hospital Affiliated to Jiangsu University, P. R. China

^dDepartment of Critical Care Medicine, Changzhou Cancer Hospital, Changzhou 213001, P. R. China

^eSchool of Chemistry and Life Sciences, Suzhou University of Science and Technology, Suzhou 215009, Jiangsu, P. R. China. E-mail: zhouyuyang@mail.usts.edu.cn

^fThe Laboratory Centre for Basic Medicine Sciences, School of Basic Medical Sciences, Nanjing Medical University, Nanjing 211166, Jiangsu, P. R. China

[†] These authors contributed equally to this work.






Fig. 2 The inhibitory effect of iridium(III) tetrazolato complexes on bacterial growth in a solid medium. (A) Inhibition ring performance. (1) 1 μ M, (2) 10 μ M, (3) 100 μ M, (4) kanamycin (control) (B) bacteriostatic effect of media with complexes. The inhibition rate was treated with a blank group as control.

Table 1 The results of inhibition ring tests (diameter/mm, $\bar{X} \pm s$, $n = 3$)

Complexes	Concentrations		
	1 μ M	10 μ M	100 μ M
Ir-CH ₃ TAZ	5.1 $\pm$ 0.30	5.7 $\pm$ 0.18	5.4 $\pm$ 0.33
Ir-TAZ	—	5.4 $\pm$ 0.21	8.4 $\pm$ 0.35
Ir-CF ₃ TAZ	5.2 $\pm$ 0.15	10.5 $\pm$ 0.50	19.5 $\pm$ 0.48
Kanamycin	—	20.5 $\pm$ 0.66	—




Fig. 3 The inhibitory effect of iridium(III) tetrazolato complexes on bacterial growth in a liquid medium. (A)

The inhibition rate = $\frac{A_B - A_S}{A_B} \times 100\%$, A_B was the absorbance value of blank control bacterial solution, A_S was the absorbance value of sample bacterial solution, (B) the removal of iridium(III) tetrazolato complexes from biofilms.

within the first hour, each complex showed a significant inhibitory impact, with bacterial growth rates significantly lower than the bacteriostasis rates, resulting in inhibition rates exceeding 100%. Notably, Ir-CF₃TAZ exhibited the highest inhibition rate (Fig. 3A). However, during the later stages of the logarithmic growth phase, the inhibition rates for all complexes decreased considerably.

Bacterial biofilms are communities of bacteria that adhere to surfaces and produce a film-like substance, comprising

polysaccharides, proteins, and lipids, which encapsulate the bacteria. Biofilm bacteria exhibit resistance to various antimicrobials, including traditional antibiotics. The ability to eradicate biofilms is a critical measure of antibacterial efficacy. Among the three complexes, Ir-CF₃TAZ and Ir-TAZ showed stronger bacteriostatic effects at low concentrations compared to Ir-CH₃TAZ. At high concentrations, however, the bacteriostatic effects of the three compounds were similar. At a concentration of 80 μ M, the biofilm removal rate peaked at approximately 90% (Fig. 3B and Table 2).

Some metal(loid)-based antimicrobials interfere with essential metal uptake and substitute essential metals in metalloproteins,^{16,17} as seen with the iridium center in Ir-CF₃TAZ. This complex might interact with amino acid residues on bacterial proteins, leading to function losing.¹⁷ Additionally, as we all know, the presence of a trifluoromethyl group not only modifies the electron distribution on the pyridine ring and enhances the nitrogen atom's coordination ability, but also possibly promotes binding to bacterial proteins through electrostatic interactions, thereby amplifying the antibacterial effect.

The destruction of the bacterial cell membrane can lead to cell death.¹⁸ The lipophilicity of 2-(2,4-fluorophenyl)pyridine allows Iridium(III) tetrazolato complexes to interact with the phospholipid bilayer of the bacterial cell membrane,^{19–21} potentially inducing structural changes and increased permeability, which can compromise the membrane's integrity. The electron-withdrawing nature of the trifluoromethyl group may render the complex partially positively charged, facilitating its binding to negatively charged cell membrane molecules through electrostatic interactions²² and further enhancing the antibacterial activity.^{23–25}

Haemolysis

In vitro haemolysis tests were conducted to evaluate the potential toxicity of iridium(III) tetrazolato complexes on erythrocytes. As shown in Fig. 4, lower values indicate a reduced likelihood of causing haemolysis. The results indicated that these complexes had minimal haemolytic effects, as evidenced by low haemolysis values. However, it's important to note that these findings are confined to *in vitro* conditions, and further *in vivo* studies and clinical trials are necessary to fully assess the safety profile of these complexes.

Overall, considering the inhibition zone, inhibition rate calculations and biofilm eradication analysis, these three iridium(III) tetrazolato complexes with their excellent

Table 2 The results of inhibition ratio for three complexes at different concentrations

Complexes	Concentrations				
	20 μ M	40 μ M	60 μ M	80 μ M	100 μ M
Ir-CH ₃ TAZ	23.8 $\pm$ 0.45	49.4 $\pm$ 0.06	51.5 $\pm$ 0.47	77.8 $\pm$ 0.26	88.3 $\pm$ 0.19
Ir-TAZ	47.6 $\pm$ 0.12	58.8 $\pm$ 0.01	69.8 $\pm$ 0.05	87.5 $\pm$ 0.55	89.2 $\pm$ 0.3
Ir-CF ₃ TAZ	47.7 $\pm$ 0.06	61.16 $\pm$ 0.03	70.1 $\pm$ 0.05	88.6 $\pm$ 0.09	89.5 $\pm$ 0.29






Fig. 4 Effect of iridium(III) tetrazolato complexes on *in vitro* haemolysis. (A) Haemolysis assay for Ir-CH₃TAZ, Ir-TAZ and Ir-CF₃TAZ. (B) Haemolysis was treated with 1% Triton X-100 as a positive control.

antimicrobial properties inevitably, show significant potential for future applications as antibacterial agents.

Conclusions

This preliminary study highlights the potential of iridium(III) tetrazolato complexes as antibacterial agents. Their antimicrobial activity, haemolytic potential and other biological properties were evaluated through inhibition zone analysis, inhibition rate calculations and haemolysis assessments. The development of metallic iridium-based drugs could offer a novel approach to combat bacterial infections, positioning them as a promising alternative to conventional antibiotics in future therapeutic strategies.

Experimental section

Inhibition ring tests

The bacteria used in this study were *Pseudomonas aeruginosa*. The experimental method was based on the filter paper slice method.²⁶ Briefly, these complexes were serially diluted tenfold from 100 μM, then added to each filter sheet discs which was then air-dried and be placed on the plate with the bacterial medium. The treated plates were placed in an incubator at 37 °C atmosphere for 24 h.

The inhibition of bacterial colony number

Different concentration of complexes was to be applied to the solid medium. Then bacteria in the logarithmic growth phase were diluted and spread on the medium plate after the complex solution had dried. After drying, the plates were placed in an incubator set at 37 °C overnight. The number of colonies was observed and determined.

Liquid antibacterial

Mixed one complex and bacterial solution each. Then incubated them in a shaker at 37 °C with constant shaking for 4 hours, following which the absorbance was measured at 600 nm using a spectrophotometer every 30 minutes.

Biofilm eradication analysis

Bacterial solutions were allowed to form biofilms in culture in a 24-well flat-bottom plate by incubation for 72 hours at 37 °C. Then they would be removed completely, and cultured with LB for 48 hours. Then different concentrations of the complex were added. And plate was shaken slowly on a shaker for 40 minutes and incubated for 24 hours at 37 °C. The non-adherent bacteria were removed by sterile ddH₂O and stained with crystal violet for the biofilm inhibition assay. The absorbance was measured at 562 nm.^{27–30}

Haemolysis

The serum was removed by centrifuging the whole blood of mice, after which the obtained blood cells were washed three times with PBS and be diluted. Incubated complex solution with blood cells at 37 °C for one hour. After that, centrifuged samples and collected the supernatant. Then the absorption value at 562 nm was determined using an enzyme marker.

Erythrocytes treated with 1% Triton X-100 were applied as a positive control, with the release of haemoglobin in this group set to 100%. The haemolysis rate of each of the other samples was calculated based on the positive control.^{31,32}

Ethical statement

All animal procedures were performed in accordance with the Guidelines for Care and Use of Laboratory Animals of Nanjing Medical University and approved by the Animal Ethics Committee of Nanjing Medical University.

Data availability

Data will be made available on request.

Author contributions

Yifei Lu: writing – original draft, data curation, formal analysis; Xiujuan Zhang: writing – original draft; Minmin Song: writing – review and editing; Hua Xie: investigation; Shuhua Chen: investigation; Yuyang Zhou: investigation, writing – review and editing; Junli Jia: conceptualization, writing – review and editing; Huamin Tang: writing – review, revision and editing, and funding acquisition.

Conflicts of interest

There are no conflicts to declare.



Acknowledgements

This work was supported by the National Natural Science Foundation of China (grants 82172263).

References

- 1 D. G. J. Larsson and C. F. Flach, Antibiotic resistance in the environment, *Nat. Rev. Microbiol.*, 2022, **20**(5), 257–269.
- 2 A. Frei, A. D. Verderosa, A. G. Elliott, J. Zuegg and M. Blaskovich, Metals to combat antimicrobial resistance, *Nat. Rev. Chem.*, 2023, **7**, 202–224.
- 3 M. S. Butler, V. Gigante, H. Sati, S. Paulin, L. Al-Sulaiman, J. H. Rex, P. Fernandes, C. A. Arias, M. Paul and G. E. Thwaites, Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed, *Antimicrob. Agents Chemother.*, 2022, **66**(3), e0199121.
- 4 A. Dong, Y. J. Wang, Y. Gao, T. Gao and G. Gao, Chemical Insights into Antibacterial N-Halamines, *Chem. Rev.*, 2017, **117**(6), 4806.
- 5 Q. Zhang, X. Tian, G. Hu, P. Shi, J. Wu, S. Li, H. Zhou, B.-K. Jin, J. Yang, S. Zhang and Y. Tian, Dual-Functional Analogous cis-Platinum Complex with High Antitumor Activities and Two-Photon Bioimaging, *Biochemistry*, 2015, **54**(13), 2177–2180.
- 6 J. K. Rybakowski, Response to Lithium in Bipolar Disorder: Clinical and Genetic Findings, *ACS Chem. Neurosci.*, 2014, **5**(6), 413–421.
- 7 H. Y. Huang, Q. Wang, C. Y. Zhang, Z. X. Chen, J. T. Wang, X. W. Liao, R. J. Yu and Y. S. Xiong, Synthesis and biological evaluation of ruthenium complexes containing phenylseleny against Gram-positive bacterial infection by damage membrane integrity and avoid drug-resistance, *J. Inorg. Biochem.*, 2023, **242**, 112175.
- 8 R. Jan, Platinum Anticancer Coordination Compounds: Study of DNA Binding Inspires New Drug Design, *Eur. J. Inorg. Chem.*, 2009, **10**(4), 1283.
- 9 Y. Yang, Y.-D. Bin, Q.-P. Qin, X.-J. Luo, B.-Q. Zou and H.-X. Zhang, Novel Quinoline-based Ir(III) Complexes Exhibit High Antitumor Activity in Vitro and in Vivo, *ACS Med. Chem. Lett.*, 2019, **10**(12), 1614–1619.
- 10 Z. Liu, A. Habtemariam, A. M. Pizarro, S. A. Fletcher, A. Kisova, O. Vrana, L. Salassa, P. C. A. Bruijninx, G. J. Clarkson, V. Brabec and P. J. Sadler, Organometallic Half-Sandwich Iridium Anticancer Complexes, *J. Med. Chem.*, 2011, **54**(8), 3011–3026.
- 11 J. Li, M. Tian, Z. Tian, S. Zhang, C. Yan, C. Shao and Z. Liu, Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P⁺P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features, *Inorg. Chem.*, 2018, **57**(4), 1705–1716.
- 12 L. Lu, L. J. Liu, W. C. Chao, H. J. Zhong, M. Wang, X. P. Chen, J. J. Lu, R. N. Li, D. L. Ma and C. H. Leung, Identification of an iridium(III) complex with anti-bacterial and anti-cancer activity, *Sci. Rep.*, 2015, **5**, 14544.
- 13 L. Guojian, P. Xixi, L. Ting, Y. Zhengyuan, X. Xiaohong and F. Chen, The Discovery of an Iridium(III) Dimer Complex as a Potent Antibacterial Agent against Non-Replicating *Mycobacterium smegmatis*, *Polymers*, 2018, **10**(3), 297.
- 14 V. Fiorini, I. Zanoni, S. Zacchini, A. L. Costa, A. Hochkoepler, V. Zanotti, A. M. Ranieri, M. Massi, A. Stefan and S. Stagni, Methylation of Ir(III)-tetrazolato complexes: an effective route to modulate the emission outputs and to switch to antimicrobial properties, *Dalton Trans.*, 2017, **46**(36), 12328–12338.
- 15 L. Gao, L. Chen, Y. Peng, Y. Zhao, J. Dong, Z. Mao, J. Jia and Y. Zhou, Iridium tetrazolato complexes as efficient protein staining agents, *Dalton Trans.*, 2022, **51**(44), 16870–16875.
- 16 L. Andrii and J. T. Raymond, Exploring antimicrobial interactions between metal ions and quaternary ammonium compounds toward synergistic metallo-antimicrobial formulations, *Microbiol. Spectr.*, 2024, **12**(10), e01047.
- 17 J. A. Lemire, J. J. Harrison and R. J. Turner, Antimicrobial activity of metals: mechanisms, molecular targets and applications, *Nat. Rev. Microbiol.*, 2013, **11**(6), 371–384.
- 18 W. Felix and A. Ariel, Mechanics and Dynamics of Bacterial Cell Lysis, *Biophys. J.*, 2019, **116**(12), 2378–2389.
- 19 M. Adriana, M. Aleksandra, B. Denise, G. Kinga, W. Joanna, H. Aleksandra, W. Robert, M.-W. Agnieszka and R.-Ż. Magdalena, Zn(II) and Cu(II) Coordination Enhances the Antimicrobial Activity of Piscidin 3, but Not That of Piscidins 1 and 2, *Inorg. Chem.*, 2024, **63**(28), 12958–12968.
- 20 S. Gu, Q. Jiang and P. Shi, Antitumor Activity and Application of Luminescent Iridium(III) Complexes, *Prog. In. Chem.*, 2022, **34**(9), 1957–1971.
- 21 S. Lin, Y. Chen, Y. Sun, G. Yu, X. Liao and Q. Yang, Evaluation of multi-target iridium(III)-based metallodrugs in combating antimicrobial resistance and infections caused by *Staphylococcus aureus*, *RSC Adv.*, 2024, **14**(23), 16194–16206.
- 22 S. Elmeharth, K. Ahsan, N. Munawar, A. Alzamly, H. L. Nguyen and Y. Greish, Antibacterial efficacy of copper-based metal-organic frameworks against *Escherichia coli* and *Lactobacillus*, *RSC Adv.*, 2024, **14**(22), 15821–15831.
- 23 N. Tripathi and M. K. Goshisht, Recent Advances and Mechanistic Insights into Antibacterial Activity, Antibiofilm Activity, and Cytotoxicity of Silver Nanoparticles, *ACS Appl. Bio Mater.*, 2022, **5**(4), 1391–1463.
- 24 X. Zhao, H. Tang and X. Jiang, Deploying Gold Nanomaterials in Combating Multi-Drug-Resistant Bacteria, *ACS Nano*, 2022, **16**(7), 10066–10087.
- 25 Z. V. Feng, I. L. Gunsolus, T. A. Qiu, K. R. Hurley, L. H. Nyberg, H. Frew, K. P. Johnson, A. M. Vartanian, L. M. Jacob, S. E. Lohse, M. D. Torelli, R. J. Hamers, C. J. Murphy and C. L. Haynes, Impacts of gold nanoparticle charge and ligand type on surface binding and toxicity to Gram-negative and Gram-positive bacteria, *Chem. Sci.*, 2015, **6**(9), 5186–5196.
- 26 M. Wenzel, M. Patra, C. H. R. Senges, I. Ott, J. J. Stepanek, A. Pinto, P. Prochnow, C. Vuong, S. Langklotz and



- N. Metzler-Nolte, Analysis of the mechanism of action of potent antibacterial hetero-tri-organometallic compounds: a structurally new class of antibiotics, *ACS Chem. Biol.*, 2013, **8**(7), 1442–1450.
- 27 M. Dargahi, Z. Hosseinidoust, N. Tufenkji and S. Omanovic, Investigating Electrochemical Removal of Bacterial Biofilms from Stainless Steel Substrates, *Colloids Surf., B*, 2014, **117**, 152.
- 28 G. Cheng, Z. Zhang, S. Chen, J. D. Bryers and S. Jiang, Inhibition of bacterial adhesion and biofilm formation on zwitterionic surfaces, *Biomaterials*, 2007, (29), 28.
- 29 A. J. Castilla-Sedano, J. Zapana-García, E. Valdivia-Del Águila, P. G. Padilla-Huamantínco and D. G. Guerra, Quantification of early biofilm growth in microtiter plates through a novel image analysis software, *J. Microbiol. Methods*, 2024, **223**, 106979.
- 30 M. Zhou, L. You, Q. Zhao, Y. Li, S. Wu and R. Huang, Progress on Bacterial Biofilm Formation and Antibiotics Resistance Mechanisms, *Adv. Microbiol.*, 2013, **2**, 98–101.
- 31 S. S. Linqi Zhu, Inhibitory Effect of Allicin on the Secretion of *Staphylococcus aureus* Virulence Factors, *Adv. Microbiol.*, 2018, **7**(2), 73–78.
- 32 Q. Wang, X. Ma, J. Jia and H. Fei, A peptide-lipid nanoparticle assembly platform with integrated functions for targeted cell delivery, *J. Mater. Chem. B*, 2016, **4**(8), 1535–1543.

